Novartis pauses screening and treatment across rapcabtagene trials
Novartis temporarily pausing screening, randomization and treatment across rapcabtagene autoleucel trials in autoimmune diseases.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.